Development of an orally delivered genital herpes vaccine: targeting the reproductive tract using Liporale, a novel lipid-based adjuvant. This project will evaluate the potential of a novel lipid-based adjuvant platform, LiporaleTM, to induce protection against a model sexually transmitted infection, genital herpes, using an orally delivered vaccination approach. Currently 16 per cent of the world's population has been exposed to herpes and there is currently no effective vaccine available.
New genes and models for inflammatory bowel disease. Inflammatory bowel disease affecting millions of people world-wide and results in a significant economic burden ($100M in Australia per year). In collaboration with Australia’s largest biotechnology company, CSL, we will use a novel approach to discover the causes of inflammatory bowel disease. This work will lead to the development of new animal models of inflammatory bowel disease that are vital for analysing the disease and testing treatmen ....New genes and models for inflammatory bowel disease. Inflammatory bowel disease affecting millions of people world-wide and results in a significant economic burden ($100M in Australia per year). In collaboration with Australia’s largest biotechnology company, CSL, we will use a novel approach to discover the causes of inflammatory bowel disease. This work will lead to the development of new animal models of inflammatory bowel disease that are vital for analysing the disease and testing treatment options. In addition, this work may lead to new approaches to treating this disease. The project will result in a greater understanding of inflammatory bowel disease, the training of highly skilled scientists and potentially lead to economically valuable knowledge.Read moreRead less
Development of purified antibodies that kill virus infected cells. This proposal will develop panels of purified and monoclonal antibodies that kill virus infected cells. These antibodies may show efficacy in preventing HIV infection. This is new technology that could subsequently be harnessed to protect or limit the devastating effects of chronic viruses such as HIV.
The Role of RNA interference in the induction of immune responses. Our work will allow us to understand a new means by which to alert the immune system to the presence of cancer cells using a new technology called RNA interference. This will hopefully lead to new investment in biotechnology products based on RNA interference, improved treatments for cancers and better health for Australians
Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory ....Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory drugs; both these treatments may have serious side effects. Cpn10 suppresses the body's inflammatory response while maintaining immune function to combat infections. The project seeks to develop new, safe and effective biopharmaceuticals based on Cpn10 for the treatment of a variety of chronic inflammatory diseases and autoimmune disorders.Read moreRead less
Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Cpn10). Diseases associated with excessive or inappropriate inflammation represent an enormous socioeconomic burden, and there is currently an urgent need to identify new targets for the development of more efficacious and safe treatments. This research seeks to provide such targets. The research may also lead to improvements in chaperonin 10 (Cpn10) treatment, which has already showing marked success in chronic inflamm ....Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Cpn10). Diseases associated with excessive or inappropriate inflammation represent an enormous socioeconomic burden, and there is currently an urgent need to identify new targets for the development of more efficacious and safe treatments. This research seeks to provide such targets. The research may also lead to improvements in chaperonin 10 (Cpn10) treatment, which has already showing marked success in chronic inflammatory disease trials. Importantly, Cpn10 appears to be anti-inflammatory rather than immunosuppressive; a critical advantage over many current anti-inflammatory interventions. Immunosuppression can lead to increased infections, which can have serious consequences, especially in elderly patients.Read moreRead less
Development of novel vaccine delivery systems for induction of mucosal immunity in a large animal model. The induction of mucosal immune responses is a highly desirable goal in vaccine research and development, as it prevents entry of the large number of mucosal pathogens. This proposal aims to develop new mucosal vaccine delivery systems by combining intra-nasal, intra-lung and transcutaneous vaccine delivery with ISCOM-based adjuvants. The nature of the immune response will be analysed in real ....Development of novel vaccine delivery systems for induction of mucosal immunity in a large animal model. The induction of mucosal immune responses is a highly desirable goal in vaccine research and development, as it prevents entry of the large number of mucosal pathogens. This proposal aims to develop new mucosal vaccine delivery systems by combining intra-nasal, intra-lung and transcutaneous vaccine delivery with ISCOM-based adjuvants. The nature of the immune response will be analysed in real time using a sheep cannulation model. Subsequently, the efficacy of mucosal vaccination strategies will be tested in a chlamydia infection model.Read moreRead less
Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine ....Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine research and development.Read moreRead less
The mucosal immune system of fish: analysis of the immune repertoire in gut-and gill-associated lymphoid tissues in trout. Infectious disease causes major economic loss to the aquaculture industry, highlighting the need for effective vaccination strategies. While oral or immersion vaccination represents the most cost effective means of protecting fish against infectious disease there are problems associated with inducing an effective immune response in fish that will assist our industry partner ....The mucosal immune system of fish: analysis of the immune repertoire in gut-and gill-associated lymphoid tissues in trout. Infectious disease causes major economic loss to the aquaculture industry, highlighting the need for effective vaccination strategies. While oral or immersion vaccination represents the most cost effective means of protecting fish against infectious disease there are problems associated with inducing an effective immune response in fish that will assist our industry partner (Novartis Animal Vaccines Ltd) to develop improved fish vaccines. The project will provide postgraduate training in the area of fish immunology that is vital to the developing Australian aquaculture industry.Read moreRead less
Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in t ....Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in the past 10 years. This project will evaluate the effectiveness of a new adjuvant as a first step towards the development of a vaccine to target these important infections.Read moreRead less